For the quarter ending 2026-03-31, IRWD had $5,015K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Loss on disposal of property and equipment | - | 3 | -7 | -85 |
| Net income (loss) | 40,773 | -2,276 | 40,080 | -13,787 |
| Depreciation and amortization | 443 | 460 | 475 | 946 |
| Share-based compensation expense | 3,653 | 3,823 | 3,612 | 9,815 |
| Non-cash interest expense | 419 | 418 | 418 | 832 |
| Non-cash lease expense | 444 | 435 | 426 | 827 |
| Deferred income taxes | 19,196 | -1,746 | 27,772 | 14,775 |
| Accounts receivable, net | 59,097 | -73,623 | 34,193 | 4,282 |
| Prepaid expenses and other current assets | -5,997 | -1,086 | 248 | 471 |
| Other assets | -121 | -100 | -63 | -284 |
| Accounts payable and accrued expenses | -4,886 | -318 | 10,693 | -4,174 |
| Accrued research and development costs | -1,102 | -274 | -1,168 | -2,664 |
| Operating lease liabilities | -621 | -612 | -603 | -1,156 |
| Other liabilities | -219 | -141 | 249 | 3,856 |
| Net cash provided by operating activities | 5,121 | 74,575 | 47,583 | 4,886 |
| Purchases of property and equipment | - | -1 | 2 | 33 |
| Net cash used in investing activities | - | 1 | -2 | -33 |
| Proceeds from exercise of stock options and employee stock purchase plan | - | 122 | 0 | 94 |
| Net cash provided by (used in) financing activities | - | 122 | 0 | 94 |
| Effect of exchange rate changes on cash and cash equivalents | -106 | 351 | -26 | -654 |
| Net increase in cash and cash equivalents | 5,015 | 75,049 | 47,555 | 4,293 |
| Cash and cash equivalents, beginning of period | 215,456 | 140,407 | 88,559 | - |
| Cash and cash equivalents, end of period | 220,471 | 215,456 | 140,407 | - |
IRONWOOD PHARMACEUTICALS INC (IRWD)
IRONWOOD PHARMACEUTICALS INC (IRWD)